<DOC>
	<DOCNO>NCT01234324</DOCNO>
	<brief_summary>That panitumumab combination Epirubicin , Cisplatin Capecitabine ( ECX ) safely decrease frequency pT3/T4 ECX alone subject locally advanced adenocarcinoma stomach gastroesophageal junction .</brief_summary>
	<brief_title>ECX + Panitumumab vs. ECX Alone Locally Advanced Gastric Cancer Cancer Gastroesophageal Junction</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Competent comprehend , sign , date IECapproved inform consent form , write informed consent . Of either gender age 18 year . Diagnosed histologically confirm adenocarcinoma stomach gastroesophageal junction Type I/II/III accord classification Siewert et al , 1996 . Stage uT/3 4 N0/+ M0 disease evaluate endoscopic ultrasound , spiral compute tomography chest , abdomen pelvis laparoscopy uT3/T4 tumor . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Leucocyte count &gt; 3,000/mm3 . Platelet count ≥100,000/mm3 . Haemoglobin ≥10 g/dl . Serum creatinine ≤ 1.5x upper limit normal ( ULN ) . Creatinine clearance &gt; 60 ml/kg/min measure either 24h urine sampling calculate use CockcroftGault formula . Aspartate aminotransferase ( AST ) ≤3 x ULN . Alanine aminotransferase ( ALT ) ≤3 x ULN . Bilirubin ≤ 1.5 x ULN . Magnesium ≥ low limit normal . Calcium ≥ low limit normal . Subject deem good candidate surgery . Any metastatic disease . Other malignant tumour less five year old . Exceptions include basocellular carcinoma , situ cancer cervix uterus , curativelytreated malignancy without evidence disease five year . Significant ascites pleural effusion . Prior antiEGFr antibody therapy ( e.g . cetuximab ) treatment small molecule EGFr tyrosine kinase inhibitor ( e.g . erlotinib ) . Prior chemotherapy , radiotherapy antibody therapy gastric cancer cancer gastrooesophageal junction . Concomitant therapy sorivudine analogue compound . Known previous ongoing abuse narcotic drug , medication alcohol . Significant cardiovascular disease include New York Heart Association ( NYHA ) grade II great congestive heart failure , peripheral arterial occlusive disease stage II great , symptomatic coronary heart disease , insufficiently treat arterial hypertension , unstable angina myocardial infarction within 12 month initiate study treatment history ventricular arrhythmia . History evidence upon physical examination CNS disease unless adequately treat , seizure control standard medical therapy , history stroke . History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis baseline chest CT scan . Preexisting polyneuropathy grade &gt; 1 accord National Cancer Institute 's Common Terminology Criteria Adverse Events ( NCI CTCAE ) , except loss tendon reflex symptom . Treatment systemic infection within 14 day initiate study treatment . Active inflammatory bowel disease , serious gastric ulceration bowel disease cause chronic diarrhoea ( define &gt; 4 loose stool per day ) . Suspected known dihydropyrimidine dehydrogenase deficiency ( DPD ) . Thrombosis severe bleeding within six month prior entry study ( except bleed tumour surgical resection ) , evidence bleed diathesis coagulopathy , current recent ( within 10 day prior initiation study treatment ) use fulldose oral parenteral anticoagulant therapeutic purpose . History medical condition may increase risk associate study participation may interfere interpretation study result . Known positive test human immunodeficiency virus infection , hepatitis C virus chronic active hepatitis B infection . Known allergy investigational product , excipients , monoclonal antibody , component chemotherapy regimen . Any comorbid disease would increase risk toxicity . Any kind disorder compromise ability subject give write informed consent and/or comply study procedure . Any investigational agent participation another clinical trial within 30 day prior randomisation . Must major surgical procedure within 28 day randomisation . Subject pregnant breast feeding . Woman man childbearing potential consenting use adequate contraceptive precaution ( intrauterine contraceptive device , contraceptive implant , injectables ( hormonal depot ) , transdermal hormonal contraception ( contraceptive patch ) , sexual abstinence vasectomise partner ) course study six month last study drug administration woman men . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . Subject unwilling unable comply study requirement . Hearing impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Stomach Neoplasms</keyword>
	<keyword>Gastroesophageal Junction Neoplasms</keyword>
	<keyword>gastric cancer</keyword>
	<keyword>cancer gastroesophageal junction</keyword>
</DOC>